AACR Tobacco and Cancer Subcommittee

The AACR Tobacco and Cancer Subcommittee was convened in 2009 to foster scientific and policy initiatives to reduce the incidence of disease and mortality due to tobacco use.

Tobacco use is the leading preventable cause of premature mortality, killing more than five million people worldwide every year. It has a particularly profound impact on cancer incidence and mortality. Indeed, tobacco use is causally associated with 18 different cancers, including lung, head and neck, stomach, pancreas, and cervical cancers, and alone tobacco accounts for 30 percent of all cancer deaths.

AACR Documents        Co-Signed Documents         News           Archived News           Subcommittee Roster

Recommendations for the Regulation of Electronic Cigarettes
An AACR-ASCO Policy Statement

On Jan. 8, 2015, the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO) released a joint statement to guide policy makers in how to best minimize the potential negative consequences of electronic nicotine delivery systems (ENDS) without undermining their potential use as a smoking cessation tool.

Electronic cigarettes (e-cigarettes) and other ENDS, which are capable of delivering a nicotine solution in aerosolized form, have been suggested as potential tobacco cessation interventions and safer alternatives to cigarettes. At the present time, however, there are insufficient data on the health consequences of e-cigarette use, their value as tobacco cessation aids, and their effects on the use of combustible tobacco products by smokers and nonsmokers.

Read the Recommendations

Electronic Nicotine Delivery Systems: A Policy Statement from the American Association for Cancer Research and the American Society of Clinical Oncology

Tobacco Use by Cancer Patients: An AACR Policy Statement

Tobacco use not only causes cancer, but it also interferes with cancer treatment and leads to poorer outcomes. The AACR has drafted a policy statement with recommendations related to tobacco use by cancer patients which calls for universal tobacco use assessment, provision of cessation treatment to all cancer patients, and the evaluation of tobacco use as a confounding factor in cancer clinical trials.

Assessing Tobacco Use by Cancer Patients and Facilitating Cessation: An American Association for Cancer Research Policy Statement

Presentation on the AACR’s tobacco policy statement by Tobacco and Cancer Subcommittee Chair, Roy S. Herbst, M.D., Ph.D.

The Science Behind Tobacco Control

The Family Smoking Prevention and Tobacco Control Act (FSPTC) of 2009 created the FDA Center for Tobacco Products (CTP) and for the first time in U.S. history created a framework for the regulation of tobacco products. The CTP’s mission to reduce the public health harms of tobacco use through evidence-based regulation of tobacco products relies on continual research as new tobacco products emerge and our understanding of the biochemical and psychological responses to tobacco use improves. The AACR is committed to working with the FDA and other policy makers to improve our understanding of the public health impact of tobacco and to reduce global tobacco use.









Subcommittee Members

Roy S. Herbst, MD, PhD, Chairperson
Yale Cancer Center
New Haven, CT

Denise Aberle, MD
University of California, Los Angeles

Los Angeles, CA

Thomas H. Brandon, PhD
H. Lee Moffitt Cancer Center & Research Institute
Tampa, FL

Geoffrey T. Fong, PhD
University of Waterloo
Ontario, CANADA

Jennifer Rubin Grandis, MD
University of Pittsburgh School of Medicine

Pittsburgh, PA

Ellen R. Gritz, PhD
The University of Texas M. D. Anderson Cancer Center
Houston, TX

Dorothy K. Hatsukami, PhD
University of Minnesota
Minneapolis, MN

Ernest Hawk, MD, MPH
The University of Texas M. D. Anderson Cancer Center
Houston, TX

Waun Ki Hong, MD, DMSc (Hon)
The University of Texas MD Anderson Cancer Center
Houston, TX

Fadlo R. Khuri, MD
Emory University

Atlanta, GA

Scott J. Leischow, PhD
The University of Arizona
Tucson, AZ

Peter G. Shields, MD
The Ohio State University Medical Center
Columbus, OH       
Benjamin Toll, PhD
Yale University School of Medicine

New Haven, CT

Kasisomayajula (Vish) Viswanath, PhD
Dana-Farber Cancer Institute
Boston, MA

Graham Warren, MD, PhD
Medical University of South Carolina
Charleston, SC

Stephanie Land, PhD, ex officio
National Cancer Institute

Rockville, MD

AACR Staff Contact

Shimere Sherwood, PhD, Associate Director of Science Policy  
AACR Office of Science Policy and Government Affairs
Email or call (202) 898-6499